November 2003
Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            
Oct   Dec


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
• PULSE Home Page
• EXECUTIVE EDITION

• US News
• Canada News
• UK News
• New Zealand News

• Consumer Advocacy
• Health Care Systems
• Managed Care/Medicaid
• Co-occurring Disorders
• Clinical studies
• Pharmaceutical News
• Criminal Justice Systems
• Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels
Archives
Adding comments
Using the # link
Items that require registration
PULSE syndication
Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Wednesday, November 12, 2003


Merck Scraps Depression Drug After Failed Trials
Reuters Health story at Medscape - "Merck & Co. Inc. on Wednesday said it has halted a late-stage trial of its experimental depression drug MK-0869, also called aprepitant, after it proved ineffective in clinical trials, dimming the company's hopes of launching the first new class of depression drugs in a decade. U.S. regulators in March approved the compound as an anti-emetic for chemotherapy patients, under the brand name Emend. Merck continued to test it under the name MK-0869 against depression, a potentially far bigger market." [Viewing Medscape resources requires registration, which is free].  
permalink